Rosacea: Diagnosis and Treatment
- PMID: 26280139
Rosacea: Diagnosis and Treatment
Abstract
Rosacea is a chronic facial skin condition of unknown cause. It is characterized by marked involvement of the central face with transient or persistent erythema, telangiectasia, inflammatory papules and pustules, or hyperplasia of the connective tissue. Transient erythema, or flushing, is often accompanied by a feeling of warmth. It usually lasts for less than five minutes and may spread to the neck and chest. Less common findings include erythematous plaques, scaling, edema, phymatous changes (thickening of skin due to hyperplasia of sebaceous glands), and ocular symptoms. The National Rosacea Society Expert Committee defines four subtypes of rosacea (erythematotelangiectatic, papulopustular, phymatous, and ocular) and one variant (granulomatous). Treatment starts with avoidance of triggers and use of mild cleansing agents and moisturizing regimens, as well as photoprotection with wide-brimmed hats and broad-spectrum sunscreens (minimum sun protection factor of 30). For inflammatory lesions and erythema, the recommended initial treatments are topical metronidazole or azelaic acid. Once-daily brimonidine, a topical alpha-adrenergic receptor agonist, is effective in reducing erythema. Papulopustular rosacea can be treated with systemic therapy including tetracyclines, most commonly subantimicrobial-dose doxycycline. Phymatous rosacea is treated primarily with laser or light-based therapies. Ocular rosacea is managed with lid hygiene, topical cyclosporine, and topical or systemic antibiotics.
Similar articles
-
Rosacea: Common Questions and Answers.Am Fam Physician. 2024 Jun;109(6):533-542. Am Fam Physician. 2024. PMID: 38905551 Review.
-
Rosacea: a review of current topical, systemic and light-based therapies.G Ital Dermatol Venereol. 2009 Dec;144(6):673-88. G Ital Dermatol Venereol. 2009. PMID: 19907406 Review.
-
Rosacea: an update.Dermatology. 2005;210(2):100-8. doi: 10.1159/000082564. Dermatology. 2005. PMID: 15724091 Review.
-
Rosacea.Br J Hosp Med (Lond). 2021 Feb 2;82(2):1-8. doi: 10.12968/hmed.2020.0417. Epub 2021 Feb 27. Br J Hosp Med (Lond). 2021. PMID: 33646026
-
Updates on the pathophysiology and management of acne rosacea.Postgrad Med. 2009 Sep;121(5):178-86. doi: 10.3810/pgm.2009.09.2066. Postgrad Med. 2009. PMID: 19820288 Review.
Cited by
-
The treatment of Tofacitinib for rosacea through the inhibition of the JAK/STAT signaling pathway.Arch Dermatol Res. 2024 Aug 24;316(8):566. doi: 10.1007/s00403-024-03314-4. Arch Dermatol Res. 2024. PMID: 39180702
-
Efficacy, Safety, and Tolerability of Oral DFD-29, a Low-Dose Formulation of Minocycline, in Rosacea: Two Phase 3 Randomized Clinical Trials.JAMA Dermatol. 2025 May 1;161(5):499-507. doi: 10.1001/jamadermatol.2024.6542. JAMA Dermatol. 2025. PMID: 40042869 Clinical Trial.
-
Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea.J Clin Aesthet Dermatol. 2020 Nov;13(11):44-49. Epub 2020 Nov 1. J Clin Aesthet Dermatol. 2020. PMID: 33282103 Free PMC article.
-
Advocacy for a shared physician/patient approach for the management of acne, rosacea, seborrheic dermatitis and photodamage.Eur J Dermatol. 2022 Jan 1;32(1):138-139. doi: 10.1684/ejd.2022.4236. Eur J Dermatol. 2022. PMID: 35653084 Free PMC article. No abstract available.
-
Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions.J Clin Aesthet Dermatol. 2021 Mar;14(3):E53-E57. Epub 2021 Mar 1. J Clin Aesthet Dermatol. 2021. PMID: 33841618 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical